Metabolic syndrome: adenosine monophosphate-activated protein kinase and malonyl coenzyme A.

Article Details

Citation

Copy to clipboard

Ruderman NB, Saha AK

Metabolic syndrome: adenosine monophosphate-activated protein kinase and malonyl coenzyme A.

Obesity (Silver Spring). 2006 Feb;14 Suppl 1:25S-33S.

PubMed ID

16642960 [ View in PubMed

]

Abstract

The metabolic syndrome can be defined as a state of metabolic dysregulation characterized by insulin resistance, central obesity, and a predisposition to type 2 diabetes, dyslipidemia, premature atherosclerosis, and other diseases. An increasing body of evidence has linked the metabolic syndrome to abnormalities in lipid metabolism that ultimately lead to cellular dysfunction. We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the adenosine monophosphate-activated protein kinase (AMPK)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism. Such dysregulation could be reflected by isolated increases in malonyl CoA or by concurrent changes in malonyl CoA and AMPK, both of which would alter intracellular fatty acid partitioning. The possibility is also raised that pharmacological agents and other factors that activate AMPK and/or decrease malonyl CoA could be therapeutic targets.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Adenosine phosphate	5'-AMP-activated protein kinase subunit beta-1	Protein	Humans	Unknown	Activator	Details